A lthough diagnosis, grading, and staging practices in bladder carcinoma have remained relatively unchanged over the last decade, some issues in the pathology diagnostics of bladder carcinoma have persisted. For instance, 2 different systems are still in place for grading of nonmuscle invasive bladder carcinoma, one based on the World Health Organization (WHO) 1973 grading system and the other applying the WHO 2004/2022 classification. The diagnosis of papillary urothelial neoplasm of low malignant potential as a separate entity has remained controversial, while its frequency has decreased substantially over time. 1 Grade heterogeneity and the presence of divergent differentiation/subtype morphology in bladder carcinoma are rather common, but their reporting is variable. Although T1 bladder carcinoma subcategorization is recommended by several international guidelines, 2,3 lack of standardization of its methodology remains an obstacle to compare larger multiinstitutional cohorts with regard to clinical outcome and treatment response. Further, many studies on molecular subtyping of bladder carcinoma have been published and multiple molecular subtyping systems coexist, some entirely based on molecular genetic testing, others on immunohistochemical stainings. 4 The clinical utility of molecular classification in current or future diagnostic pathology is not yet established. To address the above issues, the International Society of Urological Pathology (ISUP) organized the 2022 Consensus Conference on Current Issues in Bladder Cancer in Basel, Switzerland. Recommendations on these topics, based on a comprehensive literature review, while taking into account current practices, premeeting survey findings, and discussions at the conference are published in the current issue. [5][6][7][8]
MAIN FINDINGS AND RECOMMENDATIONSThe European Association of Urology (EAU)/ISUP survey among urologists and pathologists showed that the grading of nonmuscle invasive bladder carcinoma is almost exclusively reported using the WHO 2004/2022 system in North America, whereas in Europe often by both WHO 1973 and 2004/22 grading, 9 the latter in line with the 2022 EAU guideline recommendation. 10 The increasingly rare diagnosis of papillary urothelial neoplasm of low malignant potential appears mainly restricted to young patients to avoid the stigma of "cancer," while outcome data showed only minimal or no differences in clinical outcome and management strategies with noninvasive low-grade urothelial carcinoma. 1 A 3-tier hybrid grading system, separating the clinically heterogenous high-grade (WHO 2004(WHO /2022 carcinomas into a WHO 1973 grade 2 and 3 subcategory was previously proposed. 11 Literature data of several From the